Equities
Health CarePharmaceuticals and Biotechnology
  • Price (DKK)98.35
  • Today's Change2.55 / 2.66%
  • Shares traded199.41k
  • 1 Year change-46.55%
  • Beta1.1066
Data delayed at least 15 minutes, as of Jun 24 2022 15:59 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Zealand Pharma A/S is a Denmark-based biopharmaceutical company engaged in the discovery, development and commercialization of peptide-based medicines. The Company's pipeline comprises two implementation areas: Cardio-metabolic diseases and Other indications. The Cardio-metabolic diseases area includes medicines for diabetes and obesity treatment, such as Lyxumia (Lixisenatide), Lyxumia/Lantus, ZP2929 and Danegaptide. The Other indications area offers ZP1848, Elsiglutide and ZP1480 (ABT-719) drugs for inflammatory bowel disease, chemotherapy-induced diarrhea and acute kidney injury treatment. Furthermore, the Company collaborates with a number of partners, such as Sanofi, Helsinn, Boehringer Ingelheim, Abbvie and Eli Lilly.

  • Revenue in DKK (TTM)259.83m
  • Net income in DKK-957.00m
  • Incorporated1997
  • Employees345.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Calliditas Therapeutics AB194.15m-404.81m3.53bn71.00--5.92--18.19-11.38-11.385.4716.380.20771.0888.214,228,500.00-43.88-31.46-49.82-34.6817.60---211.31-288.515.36-88.310.1976--26,141.08---15.41--145.12--
Pharming Group N.V.1.40bn112.79m3.58bn321.0034.352.6314.272.560.02160.02160.26140.28180.48760.87246.04587,016.403.922.734.623.8789.3787.368.044.394.75--0.4561---6.2762.49-57.62--66.17--
Basilea Pharmaceutica AG1.09bn-50.27m3.59bn154.00------3.30-0.613-0.61312.68-4.950.6211.092.86961,831.20-2.86-6.90-5.41-9.7083.7585.05-4.61-14.701.250.1451.37--16.0617.5553.60--14.82--
Selcuk Ecza Deposu Ticaret ve Sanayi AS12.10bn495.89m3.88bn6.60k7.831.907.310.32061.911.9146.697.892.339.016.334,410,280.009.537.5026.0519.399.177.894.103.251.08--0.03522.3024.6724.8557.2530.5210.1343.21
Oxford BioMedica plc1.23bn164.37m4.00bn815.0021.432.2114.693.240.22450.22451.672.170.67817.323.58175,211.009.03-0.75611.34-0.997657.8755.2013.31-1.204.6320.400.0475--62.7738.74404.42--7.94--
Puretech Health PLC122.61m-427.01m4.11bn95.00--0.9845--33.51-0.1728-0.17280.04951.680.018--6.07149,267.80-6.484.86-8.076.24-----360.65260.53----0.08180.0047.7631.45-1,111.83--9.02--
Ergomed PLC1.03bn109.58m4.25bn1.26k39.407.2327.724.140.25050.25052.341.361.20--5.0694,486.8512.784.2719.606.1340.7841.1810.693.85--53.750.03830.0037.2624.7630.90---2.38--
Pharmanutra SpA541.15m109.75m4.41bn64.0040.1912.6438.538.151.521.527.514.841.110.81894.131,172,839.0022.6023.0629.7332.3397.0495.3920.2819.372.93--0.11350.8020.6615.75-2.1429.0318.07--
Northern Data AG121.88m-627.05m4.52bn157.00--2.11--37.05-7.25-7.251.4112.06------104,314.40---35.75---72.5737.20-6.61-514.48-343.850.301-0.52520.2519--61.18577.19-861.89------
Zealand Pharma A/S259.83m-957.00m4.58bn345.00--5.99--17.61-22.16-23.126.0216.420.12971.993.89731,901.40-47.76-31.81-57.58-37.0762.29---368.33-247.194.78--0.5268---17.194.85-20.24--53.47--
MorphoSys AG1.29bn-4.43bn4.79bn652.00--4.53--3.70-17.46-17.465.054.150.08472.041.98237,552.90-29.00-13.97-32.49-15.7379.85---342.46-89.384.15-3.060.6984---45.1929.28-625.55--55.11--
Alliance Pharma plc1.41bn63.28m5.23bn255.0083.362.1434.743.710.01350.01350.30240.52490.32242.446.74640,027.401.454.231.554.8267.0663.244.4813.501.488.110.296339.3325.7410.85-8.82-16.5631.706.92
Boiron SA3.39bn212.51m5.27bn2.77k24.761.3316.731.561.631.6325.9930.360.58641.504.89164,391.803.685.964.697.5071.9776.846.278.412.32--0.023246.86-11.37-5.828.95-18.15-10.06-9.90
Surgical Science Sweden AB339.99m70.41m5.35bn224.0059.522.0954.2715.742.542.5411.7372.320.19352.226.802,338,335.004.013.414.273.6769.0778.8020.7115.422.18--0.04320.00249.9847.90452.6692.434.25--
Eckert&Ziegler Strahlen und Mdzntchnk AG1.39bn203.41m5.80bn930.0027.993.9121.004.191.311.318.959.410.55612.435.25214,974.608.228.389.8210.1350.1847.8414.7912.772.39--0.117735.572.445.5262.2027.0840.1724.82
Cosmo Pharmaceuticals NV484.11m161.23m5.94bn290.0044.901.5025.4812.261.021.023.8930.570.09293.502.53226,830.003.09-2.093.21-2.1649.3259.6433.31-19.0512.37--0.2489--6.77-0.7776374.292.30-14.33--
Data as of Jun 24 2022. Currency figures normalised to Zealand Pharma A/S's reporting currency: Danish Krone DKK

Institutional shareholders

30.45%Per cent of shares held by top holders
HolderShares% Held
Credit Suisse Asset Management (Schweiz) AGas of 31 May 20222.17m4.97%
Polar Capital LLPas of 29 Apr 20222.15m4.92%
Wellington Management Co. LLPas of 31 Dec 20201.89m4.34%
Capital Research & Management Co. (World Investors)as of 23 Feb 20221.79m4.10%
T. Rowe Price International Ltd.as of 31 Mar 20221.38m3.16%
The Vanguard Group, Inc.as of 02 Jun 20221.19m2.74%
Norges Bank Investment Managementas of 31 Dec 20211.04m2.38%
Nykredit Bank A/S (Investment Management)as of 29 Apr 2022691.76k1.59%
BlackRock Fund Advisorsas of 02 Jun 2022505.14k1.16%
Carmignac Gestion Luxembourg SA (UK)as of 31 Mar 2021484.99k1.11%
More ▼
Data from 31 Dec 2021 - 29 Apr 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.